Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OWL-PCOS: Treatment of Hyperandrogenism vs. Insulin Resistance in Infertile PCOS Women
NCT00704912Phase 2Completed
- Sponsor
- Penn State Health Milton S. Hershey Medical Center
- Start
- Sep 2008
- Primary completion
- Mar 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of orlistat and norethindrone + ethinyl estradiol in polycystic ovary syndrome (PCOS) and infertility (3 arms), sponsored by Penn State Health Milton S. Hershey Medical Center. Primary endpoint: Live Birth Rate at 13 months. Started Sep 2008; status: completed.
02
Drugs
orlistatnorethindrone + ethinyl estradiol
03
Conditions
polycystic ovary syndrome (PCOS)infertility
Beyond the preview
Go deeper on NCT00704912.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00704912.